Recovery and Stability of Omadacycline 150-mg Crushed Tablets Dispersed in Food or Water and Administered via Nasogastric Tube
Open Access
- 2 February 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (2)
Abstract
Background: Omadacycline, an aminomethylcycline tetracycline available orally and intravenously, is approved for the treatment of patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, some of whom have difficulty swallowing tablets. The objective of this study was to assess the stability and recovery of crushed omadacycline 150-mg tablets. Methods: The recovery and stability of crushed omadacycline 150-mg tablets was assessed using 3 crushing methods (pill crusher, mortar/pestle, and sandwich bag method) and 3 dispersal products (water, vanilla syrup, or applesauce) over 24 hours at room temperature and administered via nasogastric tube. Omadacycline and its epimer (OMC-4-epimer) concentrations were assessed via liquid chromatography tandem mass spectrometry. Results: There was no significant difference in recovery of omadacycline or OMC-4-epimer proportion based on crushing technique. There were significantly higher proportions of OMC-4-epimer in applesauce experiments than in water or vanilla syrup experiments, regardless of crushing methods. All experiments had significantly less recovery of omadacycline and increased proportions of OMC-4-epimer at 24 hours compared with earlier time points. There was no significant difference in recovery of omadacycline or OMC-4-epimer proportion using either type of nasogastric tube with omadacycline recovery above 91%. Conclusions: The optimal method for recovery and stability of crushed omadacycline was to rinse the crushing device thoroughly into the collection container and disperse it into water, with consumption immediately or after no more than 4 hours. Vanilla syrup may be used as an alternative dispersal vehicle to be consumed immediately if used.Keywords
Funding Information
- Paratek Pharmaceuticals
- University of Houston
This publication has 12 references indexed in Scilit:
- Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studiesJournal of Chromatography B, 2024
- “An apple a day keeps the doctor away”: The potentials of apple bioactive constituents for chronic disease preventionJournal of Food Science, 2022
- StatPearls2021
- Prevalence and Characteristics of Dysphagia Based on a Population-Based SurveyClinical Gastroenterology and Hepatology, 2020
- Challenges in the bioanalysis of tetracyclines: Epimerisation and chelation with metalsJournal of Chromatography B, 2019
- Microbiology and Preclinical Review of Omadacycline.Clinical Infectious Diseases, 2019
- Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2016
- Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube AdministrationDrugs in R&D, 2015
- Stability and Recovery of DIFICID® (Fidaxomicin) 200-mg Crushed Tablet Preparations from Three Delivery Vehicles, and Administration of an Aqueous Dispersion via Nasogastric TubeDrugs in R&D, 2014
- Interactions with the Absorption of TetracyclinesDrugs, 1976